Adjuvant Therapy for Resected NSCLC Harboring EGFR Mutation, Chemotherapy or Targeted Therapy - PROs

被引：0
|
作者：
Zhong, W. [1 ,2 ]
机构：
[1] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Adjuvant therapy; EGFR-TKI; Lung cancer; VINORELBINE PLUS CISPLATIN;
D O I：
10.1016/j.jtho.2019.08.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PC03.01
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [1] Adjuvant targeted therapy for resected NSCLC: to be or not to be?
    Ye, Ting
    Chen, Haiquan
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3297 - S3299
  • [2] Without Radiotherapy, Comparison of Adjuvant Targeted Therapy and Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer with EGFR Sensitive Mutation
    Tang, W.
    Xie, P.
    Yu, J.
    Sun, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E534 - E534
  • [3] Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
    Wu, Y.
    John, T.
    Grohe, C.
    Majem, M.
    Goldman, J.
    Kim, S.
    Kato, T.
    Laktionov, K. K.
    Vu, H. V.
    Wang, Z.
    Lu, S.
    Lee, K. Y.
    Akewanlop, C.
    Yu, C.
    De Marinis, F.
    Bonanno, L.
    Domine, M.
    Shepherd, F.
    Zeng, L.
    Atasoy, A.
    Herbst, R.
    Tsuboi, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S113 - S114
  • [4] Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
    Wu, Yi-Long
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Goldman, Jonathan W.
    Kim, Sang-We
    Kato, Terufumi
    Laktionov, Konstantin
    Vu, Huu Vinh
    Wang, Zhijie
    Lu, Shun
    Lee, Kye Young
    Akewanlop, Charuwan
    Yu, Chong-Jen
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Zeng, Lingmin
    Atasoy, Ajlan
    Herbst, Roy S.
    Tsuboi, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : 423 - 433
  • [5] Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?
    Klevansky, Myron
    John, Thomas
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1986 - S1988
  • [6] EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations
    Tang, Wenjie
    Li, Xiaolin
    Xi, Xueqi
    Sun, Xindong
    Liu, Jie
    Zhang, Jian
    Wang, Chungang
    Yu, Jinming
    Xie, Peng
    LUNG CANCER, 2019, 136 : 6 - 14
  • [7] Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216)
    Oxnard, G.
    Mandrekar, S.
    Hillman, S.
    Tan, A.
    Govindan, R.
    Wigle, D.
    Malik, S.
    Watt, C.
    Gerber, D.
    Chaft, J.
    Dahlberg, S.
    Kelly, K.
    Faggen, M.
    Stella, P.
    Tazi, K.
    Gandara, D.
    Ramalingam, S.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S646 - S647
  • [8] ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
    Sands, Jacob
    Mandrekar, Sumithra J.
    Oxnard, Geoffrey R.
    Kozono, David E.
    Hillman, Shauna L.
    Dahlberg, Suzanne Eleanor
    Sun, Zhuoxin
    Chaft, Jamie E.
    Govindan, Ramaswamy
    Gerber, David E.
    Gray, Jhanelle Elaine
    Malik, Shakun M.
    Mooney, Margaret M.
    Janne, Pasi A.
    Vokes, Everett E.
    Kelly, Karen
    Ramalingam, Suresh S.
    Stinchcombe, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Update on adjuvant therapy in completely resected NSCLC patients
    Lim, Jeong Uk
    Yeo, Chang Dong
    THORACIC CANCER, 2022, 13 (03) : 277 - 283
  • [10] Targeted therapy outperforms chemotherapy in NSCLC
    Benmaamar, Ramla
    LANCET ONCOLOGY, 2013, 14 (08): : E296 - E296
12345